BCIQ Profiles

Company Profile ReportTarget Profile Report
0827 Xalud series C
BioCentury & Getty Images


With non-viral gene therapy in clinic, PBM-backed Xalud banks $30M series C 

Aug 27, 2021 | 10:22 PM GMT

Longtime investor PBM Capital has led Xalud’s $30 million series C round, enabling the company to continue its clinical work on a non-viral gene therapy for inflammatory

Read the full 529 word article

How to gain access

Continue reading with a
two-week free trial.